The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Apremilast Most Helpful for Mild to Moderate Psoriatic Arthritis

Apremilast Most Helpful for Mild to Moderate Psoriatic Arthritis

May 18, 2020 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

To measure disease activity and treatment progress, some rheumatologists use cDAPSA, a tool that has been adapted from measures of rheumatoid arthritis to assess more joints, such as feet, which tend to be affected in patients with PSA. cDAPSA paints a global picture of patient status and pain, according to Dr. Mease. “It’s something you can just do right there in the office. … You add all of these things together, and you’ve got your score,” he says.

You Might Also Like
  • Long-Term Apremilast Promising for Psoriatic Arthritis
  • Apremilast Effective for Psoriatic Arthritis
  • Study Results for 9 New Psoriatic Arthritis Drugs
Also By This Author
  • CD64 May Be an RA-Specific Biomarker

However, because the test primarily focuses on articular manifestations, rheumatologists are not certain patients who achieve cDAPSA targets are also achieving comprehensive disease control across a wider range of symptoms not included in the measure. Thus, the current study sought to assess the ability of cDAPSA to provide a relevant indication of comprehensive treatment responses to apremilast. The results suggest cDAPSA can be used to monitor patients using apremilast, because domains not captured by cDAPSA moved in the same direction as cDAPSA.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

According to Dr. Mease, all symptoms improved and skin and enthesitis tracked together closely. “It’s reassuring to see that a simple measure like this can work well,” he says. He notes the next step would be to see how well cDAPSA tracks patient response to other agents, such as biologics.

Patient Selection
The new findings provide a framework for rheumatologists to identify patients in clinical practice who are most likely to achieve optimal treatment responses with apremilast and monitor them. This ability is important because, according to Dr. Mease, “Apremilast does not have quite the potency of the other drugs, but its safety record is pristine.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

However, Dr. Mease cautions that safety should not be confused with tolerability. During the first month or so of apremilast use, approximately 20% of patients will experience diarrhea, headache and/or nausea. Patients who can tolerate these symptoms will likely find they abate over time. This period of adjustment can be facilitated by starting at a low dose, allowing the body to become accustomed to the treatment before adjusting to the full dose. After two to three months, the side effects should abate, and the patient should experience no safety concerns.


Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

Reference

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Mease PJ, Gladman DD, Ogdie A, et al. Treatment to target in psoriatic arthritis with apremilast: Probability of achieving targets and comprehensive control of disease manifestations. Arthritis Care Res (Hoboken). 2020 Jan 7. [Epub ahead of print]

Pages: 1 2 3 | Single Page

Filed Under: Conditions Tagged With: apremilast, cDAPSA, Clinical Disease Activity in Psoriatic Arthritis (cDAPSA), PsA, PsA Resource Center, Psoriatic Arthritis

You Might Also Like:
  • Long-Term Apremilast Promising for Psoriatic Arthritis
  • Apremilast Effective for Psoriatic Arthritis
  • Study Results for 9 New Psoriatic Arthritis Drugs
  • Apremilast Proves Effective for PsA with Skin Involvement

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)